Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China

INTRODUCTION: Bruton tyrosine kinase inhibitor (BTKi) has demonstrated substantial efficacy in treating B-cell lymphoproliferative diseases (BLPD). Nonetheless, the significant discontinuation rates due to toxicity or financial reasons cannot be overlooked. In China, empirical evidence on the usage...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Yuting, Lv, Rui, Wang, Tingyu, Yu, Ying, Huang, Yanshan, Xiong, Wenjie, Li, Yuxi, Sui, Weiwei, Wang, Qi, Huang, Wenyang, An, Gang, Zou, Dehui, Wang, Jianxiang, Qiu, Lugui, Yi, Shuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360166/
https://www.ncbi.nlm.nih.gov/pubmed/37483630
http://dx.doi.org/10.3389/fimmu.2023.1184395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360166/
https://www.ncbi.nlm.nih.gov/pubmed/37483630
http://dx.doi.org/10.3389/fimmu.2023.1184395

Ejemplares similares